

Journal section: Oral Medicine and Pathology
 Publication Types: Research

doi:10.4317/medoral.22725
<http://dx.doi.org/doi:10.4317/medoral.22725>

Periodontal treatment on patients with cardiovascular disease: Systematic review and meta-analysis

Elisabet Roca-Millan ¹, Beatriz González-Navarro ², Maria del Mar Sabater-Recolons ³, Antonio Marí-Roig ⁴, Enric Jané-Salas ², José López-López ⁵

¹ DDS, Master's student in Oral Medicine, Surgery and Implantology, Faculty of Medicine and Health Sciences (Dentistry), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain

² Department of Odontostomatology. Faculty of Medicine and Health Sciences (Dentistry), University of Barcelona // Oral Health and Masticatory System Group (Bellvitge Biomedical Research Institute) IDIBELL. University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain

³ Department of Odontostomatology, Faculty of Medicine and Health Sciences (Dentistry), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain

⁴ Specialist in Maxillofacial Surgery, Head of Department of Maxillofacial Surgery, University Hospital of Bellvitge. Catalonia, Spain. // Oral Health and Masticatory System Group (Bellvitge Biomedical Research Institute) IDIBELL. University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain

⁵ Full Professor, Department of Odontostomatology. Faculty of Medicine and Health Sciences (Dentistry) - Medical manager and Head of the medical-surgical area of Odontological Hospital University of Barcelona - University of Barcelona // Oral Health and Masticatory System Group (Bellvitge Biomedical Research Institute) IDIBELL. University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain

Correspondence:

University Campus of Bellvitge
 Pabellón de Gobierno, 2nd floor, office 2:29
 Feixa Llarga, s/n
 08907- L' Hospitalet de Llobregat
 Barcelona, Spain
18575jll@gmail.com

Roca-Millan E, González-Navarro B, Sabater-Recolons MM, Marí-Roig A, Jané-Salas E, López-López J. Periodontal treatment on patients with cardiovascular disease: Systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal. 2018 Nov 1;23 (6):e681-90.
<http://www.medicinaoral.com/medoralfree01/v23i6/medoralv23i6p681.pdf>

Received: 23/08/2018
 Accepted: 15/10/2018

Article Number: 22725 <http://www.medicinaoral.com/>
 © Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
 eMail: medicina@medicinaoral.com
Indexed in:
 Science Citation Index Expanded
 Journal Citation Reports
 Index Medicus, MEDLINE, PubMed
 Scopus, Embase and Emcare
 Índice Médico Español

Abstract

Background: Atherosclerotic cardiovascular disease is the main cause of mortality in developed countries. It is a chronic and systemic inflammatory disease with a multifactorial etiology. Periodontal disease is one of the many factors that contribute to its development.

Objective: To analyze the effects of periodontal treatment on cardiovascular risk parameters in patients with atherosclerotic cardiovascular disease.

Material and Methods: A systematic research was conducted in the Pubmed/Medline databases for clinical trials published up to and including the year 2017.

Results: Ten articles were included for analysis. Periodontal treatment reduced C-reactive protein levels (77.8% of clinical trials), tumor necrosis factor-alpha (66.7%), interleukin-6 (100%) and leukocytes (50%). Fibrinogen levels also improved considerably (66.7%). Effects on lipid parameters were more limited, whereby only oxidized low density lipoprotein and very low density lipoprotein cholesterol decreased significantly. Meta-analysis showed a

statistically significant decreased in C-reactive protein and leukocytes values when patients were submitted to non-surgical periodontal treatment in contrast to receiving no treatment at all (mean difference 1.199 mg/L, 95% confidence interval: 1.100-1.299, $p < 0.001$; and mean difference 0,79 g/L, 95% confidence interval: 0.717-0.879, $p < 0.001$, respectively).

Conclusions: Periodontal treatment has a beneficial effect on some of the biochemical parameters considered to represent cardiovascular risk. Further randomized clinical trials are necessary, with longer follow-up periods including regular periodic monitoring, in order to determine the extent of the impact of periodontal treatment.

Key words: *Periodontal disease, cardiovascular disease, atherosclerosis, periodontal therapy, periodontal treatment.*

Introduction

Atherosclerotic cardiovascular disease (ACVD) constitutes a group of chronic inflammatory pathologies that include ischemic heart disease, ischemic cerebrovascular disease, and peripheral arterial disease (1,2). It is the main cause of morbidity and mortality in industrialized countries, and of death in the world (1-3). The classic risk factors, such as hypercholesterolemia, hypertension, and smoking, only explain half the deaths of patients with this group of pathologies, and half of severe cardiovascular events (1,3). During the last 10 years, numerous published studies have investigated the relationship between ACVD and periodontal disease, because of the inflammatory basis that they share (1-7). However, research has not reached sufficiently certain conclusions to establish a causal relation between ACVD and periodontal disease. Nevertheless, on the basis of the information acquired to date, the potential positive effect of periodontal treatment on ACVD – if this can be confirmed – could constitute a new preventative/therapeutic tool (3).

There is clear scientific evidence for the important role played by inflammation in the development of ACVD (2). Epidemiological studies support the association between periodontal disease and systemic inflammation (8,9) and various meta-analyses have identified a higher risk of developing cardiovascular disease among periodontal patients (10-14). However, the effect of periodontal treatment on the atherosclerotic profile and the prevention of future cardiovascular events is not so clear (3,15). Analyzing the biochemical parameters considered cardiovascular risk factors can assess the impact of treatment. These can be grouped as inflammatory markers (C-reactive protein (CRP), tumor necrosis factor alpha (TNF- α), interleukin-6 (IL-6) and leukocytes), hemostatic or thrombotic markers, and lipid profile parameters (6).

In this context, the present systematic review was based on the following PICO question: P: periodontal treatment; I: of patients with ACVD; C: compared with non-treatment of periodontal disease; O: improvement to cardiovascular parameters.

Material and Methods

A literature search was conducted in the Pubmed database with no limitations placed on publication date. The following key search terms were applied: “Cardiovascular Disease” AND “Periodontal Treatment”; “Cardiovascular Disease” AND “Periodontal Therapy”; “Atherosclerosis” AND “Periodontal Treatment”; “Atherosclerosis” AND “Periodontal Therapy”; “Heart Disease” AND “Periodontal Therapy”; “Heart Disease” AND “Periodontal Treatment”; “Inflammatory Markers” AND “Periodontal Treatment”; and “Inflammatory Markers” AND “Periodontal Therapy”.

The titles and abstracts of all the articles located were read to select clinical trials analyzing the effect of periodontal treatment on the different clinical and biochemical parameters related to ACVD. Works not written in English or Spanish were discarded, as were animal studies. Literature reviews and meta-analyses were also excluded, as well as clinical trials that assessed the effect of periodontal treatment on cardiovascular risk in patients with diabetes or metabolic syndrome. The full text was read in case of any doubt with regard to applying these selection/exclusion criteria.

The complete texts of the selected articles were read, excluding any with patient ages below 18 years, or any that included patients without cardiovascular disease, even though the treatment applied or the parameters analyzed or objectives showed similarities to the other works selected for review.

Due to the scarcity of articles that met the inclusion criteria, studies were selected regardless of their methodology, the method of assigning treatment, sample size, follow-up period, or the clinical, biochemical or periodontal parameters assessed.

The clinical trials included for review were assessed using the Critical Appraisal Skills Program CASPe (Spanish version) (16) and the review itself was assessed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) scale (17), with 20 items.

Pooled estimates from the studies were analyzed using a continuous random-effects model meta-analysis. The

variable analyzed were changes produced in CRP and leukocytes under the following interventions: a) Oral hygiene instructions + Supragingival scaling + Root scaling and planing Vs. Oral hygiene instructions; b) Oral hygiene instructions + Supragingival scaling + Root scaling and planing Vs. Non treatment.

Forest plots were produced to graphically represent the difference in outcomes of CRP and leukocytes values. $P = 0.05$ was used as the level of significance. Heterogeneity was assessed with χ^2 test and I^2 test. The OpenMeta[analyst] tool was employed in the statistical analysis.

Results

-Identified studies

Of the 192 articles initially located in the electronic search, 134 were discarded having read titles and abstracts, as they did not fulfill the selection criteria. The full texts of the 58 remaining articles were read, excluding two works as they focused on patients aged younger

than 18 years, and 46 other works centered on patients without cardiovascular disease.

Following the selection process, the review analyzed a total of 10 clinical trials evaluating the effect of periodontal treatment on clinical and biochemical parameters involved in the development of ACVD and/or pertaining to patients diagnosed with ACVD aged over 18 years. The total population included in the studies was 669 patients (390 in intervention groups and 279 in control groups) (Fig. 1) (Tables 1, 1 continue,2).

With the exception of two of these studies (18,19), all of them excluded patients with any acute or chronic conditions that could influence systemic inflammation and distort de results obtained.

-Periodontal treatment

The periodontal treatment performed in the studies reviewed consisted of mechanical debridement (n=390) (18-27) in all cases, complemented by oral hygiene instruction (OHI) in most of them (19,20,23). In other clinical trial periodontal pockets were reduced using a




Fig. 1. Flow diagram of selection process for articles: 10 trials were selected for analysis.

Table 1. Summary of the clinical studies reviewed.

Author	Study type CASPe	N	Sample	Values registered	Periodontal parameters	Periodontal treatment	Follow-up	Significant results
Hada <i>et al.</i> (2015) (20)	RCT 7	55 (CG=25; IG=30)	CG and IG: PD and CVD	HR, RR, AP, cyanosis, jugular vein pressure, edema, jaundice, finger clubbing, CRP, leukocytes, lymphocytes, neutrophils, TC, HDL-C, LDL-C, VLDL-C, TGs	Pd, BP, CIL, ID, GI	CG: OHI; IG: OHI + tartrectomy + SRP	0, 1, 3, 6 months	↓ SAP, ↓ VLDL-C, ↓ GI, ↓ PI, ↓ PD and ↓ BP after 6 months
Offenbacher <i>et al.</i> (2009) (19)	RCT 8	37 (CG=12; IG=25)	CG and IG: PD and CVD	CRP, IL-1 β (in crevicular fluid)	PI, GI, SC, Pd, BP, CIL	CG: OHI; IG: OHI + tartrectomy + SRP	0, 6, 12 months	↓ PD after 6 months and ↓ SC after 12 months
Koppolu <i>et al.</i> (2013) (21)	RCT 9	39 (CG=19; IG=20)	CG and IG: PD and CVD	CRP, TNF- α	Pd, SOHI	CG: nothing; IG: tartrectomy + SRP	0, 2 months	↓ PD, ↓ SOHI, ↓ CRP and ↓ TNF- α
Bal <i>et al.</i> (2014) (22)	CT 6	50 (CG1=13; CG2=13; IG1=11; IG2=13)	CG1: neither PD nor CVD; CG2: no PD yes CVD; IG1: yes PD no CVD; IG2: PD and CVD	Salivary and plasma Chitotriosidase, salivary proteins	PI, GI, Pd	CG 1 and 2: nothing; IG 1 and 2: OHI + tartrectomy + SRP + pocket debridement + weekly sulcular CHX irrigation + adjoining restoration adjustment	0, 5 weeks	↓ salivary chitotriosidase, ↓ PI, ↓ GI and ↓ PD
Rastogi <i>et al.</i> (2012) (27)	CT 6	20 (IG=20)	PD and CVD	CRP, TNF- α , leukocytes	Pd, BP	IHO + tartrectomy + SRP	0, 1 month	↓ PD, ↓ BP, ↓ CRP and ↓ leukocytes
Higashi <i>et al.</i> (2009) (18)	RCT 10	101 (CG1: 24; CG2=53; IG=24)	CG1: PD and CVD; CG2: no PD yes CVD; IG: PD and CVD	AP, HR, TC, HDL-C, LDL-C, TGs, glucose, insulin, IL-6, CRP, FBF response to ACh and SNP, MDA, 8-OHdG	BP, Pd, CIL	CG 1 and 2: nothing; IG: OHI + SRP + antibiotics after intensive treatment	0, 6 months	↓ CRP, ↓ IL-6, ↓ PD, ↓ CIL, ↓ BP and ↑ FBF response to Ach
Zhou <i>et al.</i> (2013) (24)	CT 8	75 (CG=35; IG=40)	CG and IG: PD and CVD	CRP, TNF- α , IL-6, glucose, TC, LDL-C, HDL-C, TGs, leukocytes	BI, PI, Pd, CAL	CG: OHI; IG: OHI + tartrectomy + SRP	0, 3 months	↓ BI, ↓ PI, ↓ PD, ↓ CAL, ↓ CRP, ↓ IL-6, ↓ TNF- α y ↓ LDL-C

Table 1 continue. Summary of the clinical studies reviewed.

Bokhari <i>et al.</i> (2012) (25)	RCT 9	246 (CG=85; IG=161)	CG and IG: PD and CVD	CRP, FGN, leukocytes	BP, Pd, CAL	CG: nothing; IG: OHI + tartrectomy + SRP	0, 1, 2 months	↓ BP, ↓ PD, ↓ CRP and ↓ leuko- cytes after 1 and 2 months; ↓ FGN after 2 months
Bokhari <i>et al.</i> (2009) (23)	CT 8	28 (IG1=17; IG2=11)	IG1: PD and CVD; IG2: yes PD no CVD	CRP, FGN, leukocytes	Pd, BP	IG 1 and 2: OHI + tar- trectomy + SRP	0, 1 month	↓ PD, ↓ BP, ↓ CRP, ↓ FGN and ↓ leukocytes
Montebugnoli <i>et al.</i> (2005) (26)	CT 9	18 ^(#) (CG=IG=18)	PD and CVD	CRP, FGN, leukocytes, vWF, ox-LDL, dimer-D	CPSS (Pd, BP, SUP, FD), CRSS (FD, RVBL)	OHI + tar- trectomy + SRP	0, 4 (control period), 7 months (3 months in- tervention period)	↓ CPSS, ↓ CRSS, ↓ CRP and ↓ ox-LDL

Abbreviations: 8-OHdG: 8-hydroxy-2'-deoxyguanosine; Ach: acetylcholine; AP: arterial pressure; BI: bleeding index; BP: bleeding on probing; CAL: clinical attachment loss; CASPe (16): critical appraisal skills program (Spanish version); CG: control group; CG1: control group 1; CG2: control group 2; CHX: chlorhexidine; CIL: clinical insertion level; CPSS: clinical periodontal sum score; CRP: C-reactive protein; CRSS: clinical and radiographic sum score; CT: clinical trial; CVD: cardiovascular disease; FBF: forearm blood flow; FD: furcation defects; FGN: fibrinogen; GI: gingival index; HDL-C: high density lipoprotein cholesterol; HR: heart rate; IG: intervention group; IG1: intervention group 1; IG2: intervention group 2; IL-1β: interleukin-1-beta; IL-6: interleukin -6; LDL-C: low density lipoprotein cholesterol; MDA: malondialdehyde; OHI: oral hygiene instruction; ox-LDL: oxidized LDL; PD: periodontal disease; Pd: probe depth; PI: plaque index; RCT: Randomized clinical trial; RR: respiratory rate; RVBL: radiological vertical bone loss; SAP: systolic arterial pressure; SC: subgingival calculus; SNP: sodium nitroprusside; SOHI: simplified oral hygiene index; SRP: scaling and root planing; SUP: suppuration on probing; TC: total cholesterol; TGs: triglycerides; TNF-α: tumor necrosis factor alpha; VLDL-C: very low density lipoprotein cholesterol; vWF: von Willebrand factor. (#) All parameters were determined in each subject at baseline, after 4 months as a control and 3 months after an intensive protocol of scaling and root planning.

Table 2. Summary of main results.

Hada <i>et al.</i> (2015) (20)	Reduction in systolic blood pressure and very-low-density lipoproteins values.
Offenbacher <i>et al.</i> (2009) (19)	No significant effect on serum C-reactive protein levels.
Koppolu <i>et al.</i> (2013) (21)	Decreased values of C-reactive protein and tumor necrosis factor alpha.
Bal <i>et al.</i> (2014) (22)	Reduction in salivary chitotriosidase activity.
Rastogi <i>et al.</i> (2012) (27)	Decrease in C-reactive protein and white blood cells levels.
Higashi <i>et al.</i> (2009) (18)	Reduction in C-reactive protein and interleukin-6 concentrations; increase in acetylcholine-induced vasodilation.
Zhou <i>et al.</i> (2013) (24)	Improvement in tumor necrosis factor alpha, interleukin-6, C-reactive protein and low-density lipoproteins-cholesterol values.
Bokhari <i>et al.</i> (2012) (25)	Decrease in C-reactive protein, fibrinogen and white blood cells levels.
Bokhari <i>et al.</i> (2009) (23)	Reduction in C-reactive protein, fibrinogen and white blood cells values.
Montebugnoli <i>et al.</i> (2005) (26)	Improvement in C-reactive protein and oxidized-low density lipoprotein concentrations.

diamond bur (n=24) (22), and in another, antibiotic therapy was used in some cases depending on the intensity of the treatment applied (n=24) (18).

Selected articles did not show homogeneity in the diagnosis of periodontal disease. In the vast majority the term chronic periodontitis was used without specifying the degree, with exception of one in which patients with chronic gingivitis and mild to moderate periodontitis were included (20).

-ACVD diagnosis

The criteria defining cardiovascular pathology differed from study to study. In some cases, patients with previous histories of cardiovascular events (n=94) (20,21) were included, in others, patients with obstruction over 50% or over 70% in at least one artery (n=43) (22,23), or both (n=477) (18,19,24-26). In one article, subjects had been diagnosed with coronary artery pathology, although this was not specified in detail (n=20) (27).

-Periodontal parameters

The variables used to objectify improvement in periodontal status in all the studies reviewed were: probe depth, bleeding on probing, and gingival index. Clinical insertion level was measured in half the works (18-20,24,25). Follow-up periods ranged between one month and one year, with a mean of 15 weeks.

-Cardiovascular parameters

Regarding the cardiovascular risk parameters assessed, nine works analyzed CRP, (18-21,23-27) observing significant reductions in CRP levels after periodontal treatment (n=311) (18,21,23-27). TNF- β was studied in three of the trials (21,24,27), finding a statistically significant reduction in two of them (n=60).(21,24) IL-6 was only measured in two works (18,24) observing significant reductions after periodontal treatment (n=64). IL-1 α levels were only analyzed in a single work in crevicular fluid samples, but did not present any significant improvement after periodontal treatment (19).

As for lipid profiles, three works (18,20,24) analyzed plasma levels of total cholesterol, LDL-C, HDL-C and triglycerides. None of them observed significant changes in total cholesterol levels, HDL-C or triglycerides after periodontal treatment. Only one of them observed a significant reduction in LDL-C resulting from treatment (n=40) (24). A study conducted on 18 patients measured oxidized LDL, obtaining a significant reduction in levels after treatment (n=18) (26). VLDL cholesterol was only measured in one work,(20) also obtaining a significant reduction (n=30).

Total leukocyte levels were analyzed in six studies (20,23-27), observing significant reductions in three of them after periodontal treatment (n=209) (23,25,27). One of this clinical trials also measured lymphocyte and neutrophil levels individually, but did not observe any differences resulting from periodontal treatment (20). None of these six works included antibiotic therapy

in periodontal treatment. Two of the three studies (23,25,26) that studied fibrogenin observed significant reductions (n=189) (23,25). Glucose levels were measured in two studies (18,24) but neither saw any changes. No significant changes were obtained regarding insulin levels after periodontal treatment (18).

-Other parameters

One work evaluated salivary and plasma chitotriosidase (enzyme produce by activated macrophages) and salivary proteins (22). After periodontal treatment, a significant reduction in the salivary enzyme was observed (n=24), but not in plasma or in the salivary proteins evaluated.

Another study (26) measured von Willebrand factor and fibrin D-dimer but did not observe significant differences after periodontal treatment.

Other parameters analyzed in the studies were malondialdehyde-modified LDL, 8-hydroxy-2'-deoxyguanosine, and forearm blood flow response to acetylcholine and sodium nitroprusside (18). After periodontal treatment, significant changes were observed in blood flow response to acetylcholine, considerably increasing vasodilation (n=24).

Heart rate and blood pressure were analyzed in two of the works (18,20). The only significant result was a reduction in systolic blood pressure observed in the first study (n=30) (20). This one also analyzed other clinical parameters (respiratory rate, the presence of cyanosis, jugular venous pressure, edema, jaundice, and soft tissue enlargement (clubbing) of the fingers) but no significant changes were produced in any of these parameters after treatment.


-CRP and leukocytes Meta-analysis

Separate meta-analysis was performed to analyze the mean differences of CRP between studies. Three studies (19,20,24) evaluated values of CRP before and after the administration of Oral hygiene instructions + Supragingival scaling + Scaling and root planning in the treatment group (n= 95) Vs. Oral hygiene instructions in the control group (n=72). The forest plot (Fig. 2a) shows a CRP mean difference of 0.03mg/l and a *p* value = 0.966 (95% CI: -1.353 to 1.414, heterogeneity I² =0%, *P*=0.766).

Four studies (18,21,25,26) assessed values of CRP before and after the administration of Oral hygiene instructions + Supragingival scaling + Scaling and root planing in the treatment group (n= 223) Vs. Non treatment in the control group (n=146). The forest plot (Fig. 2b) shows a CRP mean difference of 1.199 mg/l and a *p* value = <0.001 (95% CI: 1.100 to 1.299, heterogeneity I² =0%, *P*=0.918).

Also a meta-analysis was performed to analyze the mean differences of leukocytes between studies. Two studies (22,30) evaluated values of leukocytes before and after the administration of Oral hygiene instructions

2a



2b




Fig. 2. (a) Forest plot: studies evaluating CRP values before and after the administration of Oral hygiene instructions + Supragingival scaling + Scaling and root planing in the treatment group Vs. Oral hygiene instructions in the control group. (b) Forest plot: studies evaluating CRP values before and after the administration of Oral hygiene instructions + Supragingival scaling + Scaling and root planing in the treatment group Vs. Non treatment.

tions + Supragingival scaling + Root scaling and planing in the treatment group (n= 70) Vs. Oral hygiene instructions in the control group (n=60). The forest plot (Fig. 3a) shows a leukocytes mean difference of 0.67 g/l and a *p* value = 0.158 (95% CI: -0.260 to 1.596, heterogeneity I² =0%, *P*=0.321).

Two studies^{31,32} assessed values of leukocytes before and after the administration of Oral hygiene instructions + Supragingival scaling + Root scaling and planing in the treatment group (n= 179) Vs. Non treatment in the control group (n=103). The forest plot (Fig. 3b) shows a leukocytes mean difference of 0.79 g/l and a *p* value = <0.001 (95% CI: 0.717 to 0.879, heterogeneity I² =0%, *P*=0.484).

Discussion


A 2017 Cochrane systematic review of randomized clinical trials conducted among patients with periodontal disease and ACVD antecedents (secondary prevention) or patients with periodontal disease but without ACVD antecedents (primary prevention), failed to find sufficient evidence to support or refute the possibility that periodontal treatment prevents or delays the recurrence of ACVD; no evidence for primary prevention of ACVD was found. However, this review only included a single clinical trial, in which part of the control group

received non-surgical periodontal treatment outside the study within the follow-up period (28).

In the works analyzed in the present literature review, most of the studies that analyzed CRP levels after periodontal treatment (18,21,23-27) observed statistically significant reductions in this parameter with two exceptions (19,20). The periodontal treatment applied was the same in all six studies, but the different outcomes could be explained by the fact that in one work were included patients with advanced chronic gingivitis rather than severe chronic periodontitis, and that baseline values were significantly different between the intervention and control groups (20). In another clinical trial, control group patients were permitted to undergo periodontal treatment independently of the study, so that the real periodontal attention received by these patients was unknown, a factor that could exert some influence in the absence of differences in periodontal status between the groups after treatment (19).

In two trials conducted with samples of 39 (21) and 75 (24) subjects with follow-ups of 2 and 3 months respectively, the intervention groups underwent mechanical rather than surgical debridement, obtaining statistically significant reductions (*p*<0.05) in TFN- α values after periodontal treatment. But a study that applied the same treatment to a sample of 20 patients with a 1-month

3a



3b




Fig. 3. (a) Forest plot of studies evaluating leukocytes values before and after the administration of Oral hygiene instructions + Supragingival scaling + Root scaling and planning in the treatment group vs. Oral hygiene instructions in the control group. (b) Forest plot of studies evaluating leukocytes values before and after the administration of Oral hygiene instructions + Supragingival scaling + Root scaling and planning in the treatment group vs. Non treatment.

follow-up, did not observe significant changes ($p>0.05$) in this parameter (27). This could be due to the small sample size or the brief follow-up period.

Two of the works that studied IL-6 obtained significant reductions ($p<0.05$) in levels after periodontal treatment (18,24). So, it may be deduced that mechanical debridement reduces serum levels of this soluble protein in this type of patient. The same did not occur with IL-1 β , registered in a sample of 37 patients with a 12-month follow-up (19). However, this study obtained values proceeding from crevicular fluid, which were not correlated to serum levels.

Mechanical debridement of periodontal tissues would appear unrelated to improvements in total cholesterol, HDL-C and triglyceride levels, as none of the three trials (18,20,24) that analyzed these parameters observed significant changes ($p>0.05$). Nevertheless, it seems that periodontal treatment could be related to LDL, VLDL and oxidized LDL levels, as these values decreased significantly in three works ($p<0.05$, $p<0.05$, $p<0.01$ respectively) (20,24,26). If these parameters can be improved by periodontal treatment, this could constitute a valuable means of ACVD prevention, as these are some of the main components of atheromatous plaque (6).

Improving periodontal status could also be associated

with a reduction in total leukocytes. Half of the trials that analyzed this parameter obtained significant reductions ($p<0.05$) in values (23,24,27), although the other three studies that looked into this parameter (20,24,26) did not observe significant changes. Studies with follow-up periods of 1 or 2 months observed significant changes (23,25,27), while the others had longer follow-up periods. This suggests that perhaps leukocyte levels only respond to periodontal treatment for a limited period. These results coincide with the meta-analysis performed where a significant difference was found when oral hygiene instructions + supragingival scaling + root scaling and planning were applied compared to non-treatment.

Fibrinogen levels appear to act similarly, as significant reductions ($p<0.05$) were observed in two trials with shorter follow-up periods of between 1 and 2 months after periodontal treatment (23,25). But in a study with a 3-month follow-up (in which no intermediate measurements were performed) no changes were produced (26). This could be explained by the possibility that fibrinogen responded to mechanical debridement for a brief period, or perhaps due to reductions in gingival bleeding after treatment.

Glycemia was analyzed in two works (18,24) with fol-

low-up periods of 6 and 3 months respectively. Neither of these observed significant reductions in glycemia ($p>0.05$) after periodontal treatment, which could be due to this parameter's poor response to mechanical debridement or to improvements in periodontal status, or to the possibility that the effect only continued for a limited period. The first of these two studies also registered insulin levels with the same results.

Nor was periodontal treatment seen to reduce plasma chitotriosidase or salivary proteins, although salivary chitotriosidase levels were reduced ($p=0.005$) (22). Improvements in periodontal status could be associated with the reestablishment of some salivary parameters, which do not extend to systemic improvement.

Mechanical debridement did not appear to have any effect on von Willebrand factor or on fibrin D-dimer, although further trials are necessary to confirm this, as the present review only found a single study that investigated these parameters (26).

Blood flow response to acetylcholine increased considerably ($p<0.001$) after periodontal treatment, improving the endothelial dysfunction typical of periodontal patients (18). However, no changes in malondialdehyde-modified LDL, 8-hydroxy-2'-deoxyguanosine, or forearm blood flow response to sodium nitroprusside were observed. As this analysis took place at the end of a 6-month follow-up, there could have been some short-term improvement that was not registered.

Only two of the works reviewed considered non-analytic parameters (18,20), and the only parameter to show a statistically significant improvement ($p<0.05$) was systolic blood pressure (20). Further studies with longer follow-up periods would be needed to determine whether periodontal treatment improves clinical parameters of cardiovascular patients beyond the biochemical parameters analyzed in most of the trials conducted to date.

In agreement with the findings of the present review, a meta-analysis published in 2014 concluded that periodontal treatment improves endothelial function and the atherosclerotic profile of periodontal patients with ACVD and/or diabetes (29). Similarly, an earlier 2013 systematic review affirmed that periodontal treatment produces a progressive reduction in systemic inflammation and improvements in endothelial function. However, there is no evidence that these changes have any long-term effect on cardiovascular risk in patients with periodontitis (3).

Lastly, another meta-analysis that focused on CRP values alone concluded that non-surgical periodontal treatment reduced serum levels of this protein (30). This agrees with the results obtained in the meta-analysis performed in the present review, where a decreased in CRP values was noted to be statistically significant when patients were submitted to non-surgical periodontal treatment in contrast to receiving no treatment at all.

Even the positive results obtained, considering the limitations discussed throughout the study, more homogeneous clinical trials, with larger samples, more detailed methodology and longer follow-up periods are needed in order to generalize these findings.

In conclusion, periodontal treatment can improve some biochemical parameters involved in the development of ACVD, including CRP, TNF- α , IL-6, fibrinogen, leukocytes, oxidized LDL, and VLDL-C. The non-analytic parameters investigated did not respond to periodontal treatment. Further clinical studies with longer follow-up periods and regular periodic analyses are necessary to establish the effect of non-surgical periodontal treatment on patients with ACVD.

References

1. Aarabi G, Eberhard J, Reissmann DR, Heydecke G, Seedorf U. Interaction between periodontal disease and atherosclerotic vascular disease - Fact or fiction? *Atherosclerosis*. 2015;241:555-60.
2. Lockhart PB, Bolger AF, Papananou PN, Osinbowale O, Trevisan M, Levison ME, et al. Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association?: a scientific statement from the American Heart Association. *Circulation*. 2012;125:2520-44.
3. D'Aiuto F, Orlandi M, Gunsolley JC. Evidence that periodontal treatment improves biomarkers and CVD outcomes. *J Periodontol*. 2013;84:S85-105.
4. Tonetti MS, Van Dyke TE, Working group 1 of the joint EEP/AAP workshop. Periodontitis and atherosclerotic cardiovascular disease: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. *J Clin Periodontol*. 2013;40:S24-9.
5. Van Dyke TE, van Winkelhoff AJ. Infection and inflammatory mechanisms. *J Clin Periodontol*. 2013;40:S1-7.
6. Schenkein HA, Loos BG. Inflammatory mechanisms linking periodontal diseases to cardiovascular diseases. *J Clin Periodontol*. 2013;40:S51-69.
7. Dietrich T, Sharma P, Walter C, Weston P, Beck J. The epidemiological evidence behind the association between periodontitis and incident atherosclerotic cardiovascular disease. *J Clin Periodontol*. 2013;40:S70-84.
8. Loos BG, Craandijk J, Hoek FJ, Wertheim-van Dillen PM, van der Velden U. Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. *J Periodontol*. 2000;71:1528-34.
9. Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E. Periodontal infections contribute to elevated systemic C-reactive protein level. *J Periodontol*. 2001;72:1221-7.
10. Xu S, Song M, Xiong Y, Liu X, He Y, Qin Z. The association between periodontal disease and the risk of myocardial infarction: a pooled analysis of observational studies. *BMC Cardiovasc Disord*. 2017;17:50.
11. Humphrey LL, Fu R, Buckley DI, Freeman M, Helfand M. Periodontal disease and coronary heart disease incidence: a systematic review and meta-analysis. *J Gen Intern Med*. 2008;23:2079-86.
12. Bahekar AA, Singh S, Saha S, Molnar J, Arora R. The prevalence and incidence of coronary heart disease is significantly increased in periodontitis: a meta-analysis. *Am Heart J*. 2007;154:830-7.
13. Leng WD, Zeng XT, Kwong JS, Hua XP. Periodontal disease and risk of coronary heart disease: An updated meta-analysis of prospective cohort studies. *Int J Cardiol*. 2015;201:469-72.
14. Zeng XT, Leng WD, Lam YY, Yan BP, Wei XM, Weng H, et al. Periodontal disease and carotid atherosclerosis: A meta-analysis of 17,330 participants. *Int J Cardiol*. 2016;203:1044-51.
15. Li C, Lv Z, Shi Z, Zhu Y, Wu Y, Li L, et al. Periodontitis therapy

for the management of cardiovascular disease in patients with chronic periodontitis. *Cochrane Database Syst Rev.* 2014;8:CD009197.

16. Cuesta-Vargas AI, Galán-Mercant A, Williams JM. The use of inertial sensors system for human motion analysis. *Phys Ther Rev.* 2010;15:462-73.

17. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med.* 2009;6:e1000097.

18. Higashi Y, Goto C, Hidaka T, Soga J, Nakamura S, Fujii Y, et al. Oral infection-inflammatory pathway, periodontitis, is a risk factor for endothelial dysfunction in patients with coronary artery disease. *Atherosclerosis.* 2009;206:604-10.

19. Offenbacher S, Beck JD, Moss K, Mendoza L, Paquette DW, Barrow DA, et al. Results from the Periodontitis and Vascular Events (PAVE) Study: a pilot multicentred, randomized, controlled trial to study effects of periodontal therapy in a secondary prevention model of cardiovascular disease. *J Periodontol.* 2009;80:190-201.

20. Hada DS, Garg S, Ramteke GB, Ratre MS. Effect of non-surgical periodontal treatment on clinical and biochemical risk markers of cardiovascular disease: a randomized trial. *J Periodontol.* 2015;86:1201-11.

21. Koppolu P, Durvasula S, Palaparthy R, Rao M, Sagar V, Reddy SK, et al. Estimate of CRP and TNF-alpha level before and after periodontal therapy in cardiovascular disease patients. *Pan Afr Med J.* 2013;15:92.

22. Bal MV, Olgun A, Abaslı D, Özdemir A, Kürşaklıoğlu H, Göktepe AS, et al. The effect of nonsurgical periodontal treatment on serum and saliva chitotriosidase activities in patients with periodontitis and coronary artery disease. *Ther Clin Risk Manag.* 2014;11:53-8.

23. Bokhari SA, Khan AA, Tatakis DN, Azhar M, Hanif M, Izhar M. Non-surgical periodontal therapy lowers serum inflammatory markers: a pilot study. *J Periodontol.* 2009;80:1574-80.

24. Zhou SY, Duan XQ, Hu R, Ouyang XY. Effect of non-surgical periodontal therapy on serum levels of TNF- α , IL-6 and C-reactive protein in periodontitis subjects with stable coronary heart disease. *Chin J Dent Res.* 2013;16:145-51.

25. Bokhari SA, Khan AA, Butt AK, Azhar M, Hanif M, Izhar M, et al. Non-surgical periodontal therapy reduces coronary heart disease risk markers: a randomized controlled trial. *J Clin Periodontol.* 2012;39:1065-74.

26. Montebugnoli L, Servidio D, Miaton RA, Prati C, Tricoci P, Melloni C, et al. Periodontal Health improves systemic inflammatory and haemostatic status in subjects with coronary heart disease. *J Clin Periodontol.* 2005;32:188-92.

27. Rastogi P, Singhal R, Sethi A, Agarwal A, Singh VK, Sethi R. Assessment of the effect of periodontal treatment in patients with coronary artery disease: A pilot survey. *J Cardiovasc Dis Res.* 2012;3:124-7.

28. Li C, Lv Z, Shi Z, Zhu Y, Wu Y, Li L, et al. Periodontal therapy for the management of cardiovascular disease in patients with chronic periodontitis. *Cochrane Database Syst Rev.* 2017;11:CD009197.

29. Teeuw WJ, Slot DE, Susanto H, Gerdes VE, Abbas F, D'Aiuto F, et al. Treatment of periodontitis improves the atherosclerotic profile: a systematic review and meta-analysis. *J Clin Periodontol.* 2014;41:70-9.

30. Freitas CO, Gomes-Filho IS, Naves RC, Nogueira Filho Gda R, Cruz SS, Santos CA, et al. Influence of periodontal therapy on C-reactive protein level: a systematic review and meta-analysis. *J Appl Oral Sci.* 2012;20:1-8.

Source of Funding Statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of Interest

None.